RxSight, Inc. (NASDAQ:RXST – Get Free Report) insider Ilya Goldshleger sold 1,330 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $46.13, for a total transaction of $61,352.90. Following the completion of the sale, the insider now owns 42,246 shares in the company, valued at approximately $1,948,807.98. The trade was a 3.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Ilya Goldshleger also recently made the following trade(s):
- On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $51.91, for a total transaction of $161,180.55.
- On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.79, for a total transaction of $154,349.00.
- On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.64, for a total transaction of $156,984.00.
- On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total value of $154,008.00.
- On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,529.45.
- On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total value of $154,318.00.
- On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total transaction of $155,589.00.
- On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,279.00.
- On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
- On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total value of $148,831.00.
RxSight Trading Up 2.0 %
Shares of RXST stock opened at $45.05 on Friday. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -54.28 and a beta of 1.19. The firm’s 50 day moving average is $50.32 and its 200-day moving average is $53.27. RxSight, Inc. has a 1 year low of $27.07 and a 1 year high of $66.54.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on RXST
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of RXST. CWM LLC grew its holdings in RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares during the period. Nisa Investment Advisors LLC boosted its holdings in RxSight by 854.1% during the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after purchasing an additional 521 shares during the last quarter. Quarry LP boosted its position in RxSight by 82.3% during the third quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after purchasing an additional 288 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of RxSight in the third quarter valued at $34,000. Finally, Quest Partners LLC acquired a new position in shares of RxSight during the 2nd quarter worth about $41,000. Institutional investors and hedge funds own 78.78% of the company’s stock.
About RxSight
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Read More
- Five stocks we like better than RxSight
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- MarketBeat Week in Review – 11/11 – 11/15
- What is the Dogs of the Dow Strategy? Overview and Examples
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Consumer Discretionary Stocks Explained
- Top-Performing Non-Leveraged ETFs This Year
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.